Abstract Number: 2630 • 2019 ACR/ARP Annual Meeting
A Dutch Consensus Statement on the Diagnosis and Treatment of ANCA Associated Vasculitis
Background/Purpose: Several guidelines have been published on the diagnosis and treatment of anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV). These guidelines provide an evidence-based approach…Abstract Number: 810 • 2019 ACR/ARP Annual Meeting
Small Vessel Vasculitis Syndrome with Autoinflammation Caused by De Novo Mutations in LYN Kinase
Background/Purpose: Lyn kinase is a member of the Src family of non-receptor tyrosine-protein kinases that modifies signals from various cell surface receptors and regulates innate…Abstract Number: 1681 • 2019 ACR/ARP Annual Meeting
The Association of Reduced Low-Density Lipoprotein (LDL) Cholesterol Levels with ANCA-Associated Vasculitis (AAV)
Background/Purpose: ANCA-associated vasculitis (AAV) is a small vessel vasculitis associated with an intense inflammatory state. AAV patients are at a 2-fold higher risk of cardiovascular…Abstract Number: 2632 • 2019 ACR/ARP Annual Meeting
Changing Trends in the Management of ANCA-associated Vasculitis at an Academic Medical Center
Background/Purpose: For years, cyclophosphamide (CYC) has been the primary treatment for severe anca-associated vasculitides (AAV) and has significantly improved disease related mortality. In addition, maintenance…Abstract Number: 869 • 2019 ACR/ARP Annual Meeting
Clinical Manifestations of Patients with Eosinophilic Granulomatosis with Polyangiitis in a Large North American Cohort
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, systemic necrotizing small-vessel vasculitis, with only a few published North American series. This project aimed to…Abstract Number: 1687 • 2019 ACR/ARP Annual Meeting
Dramatic but Suspensive Effect of interleukin-1 Inhibitors on Persistent Urticarial Vasculitis
Background/Purpose: Urticarial vasculitis (UV) is a rare disease characterized by dermal capillary inflammation responsible for long-lasting urticarial lesions. UV can be separated into 2 different…Abstract Number: 2634 • 2019 ACR/ARP Annual Meeting
ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients
Background/Purpose: Recent studies have demonstrated that in patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) with successful remission-induction (RI) after cyclophosphamide (CYC), maintenance treatment with…Abstract Number: 871 • 2019 ACR/ARP Annual Meeting
ANCA-Associated Vasculitis Management in the United States: Data from the RISE Registry
Background/Purpose: The management of ANCA-associated vasculitis (AAV) evolved substantially in recent years because of evidence supporting the efficacy of various treatment regimens. As such, treatment…Abstract Number: 1688 • 2019 ACR/ARP Annual Meeting
Glucocorticoids Plus Rituximab versus Glucocorticoids Plus Placebo in Non-infectious Active Mixed Cryoglobulinemia Vasculitis: Results of a Placebo-Controlled Randomized Trial
Background/Purpose: A previous retrospective study suggested superiority of glucocorticoids (GCs) plus rituximab (RTX) compared to GCs alone to induce complete clinical response in non-infectious cryoglobulinemia…Abstract Number: 2635 • 2019 ACR/ARP Annual Meeting
Accuracy of Self-Reported Diagnosis of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Background/Purpose: To determine the reliability of self-reported diagnosis of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with…Abstract Number: 873 • 2019 ACR/ARP Annual Meeting
Survival After Lung Transplantation in Adults with Primary Systemic Vasculitides: Analysis of the United Network of Organ Sharing (UNOS) Database
Background/Purpose: Pulmonary involvement, including pulmonary vascular disease and interstitial lung disease can be an important cause of morbidity and even mortality in patients with primary…Abstract Number: 1704 • 2019 ACR/ARP Annual Meeting
Efficacy of Leflunomide for Treatment of Vasculitis
Background/Purpose: Only a few small case series, case reports, and one small clinical trial suggested some benefit of leflunomide (LEF) in ANCA-associated vasculitis and other…Abstract Number: 2638 • 2019 ACR/ARP Annual Meeting
The Cumulative Burden of Damage for Patients with Eosinophilic Granulomatosis with Polyangiitis
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by asthma and other manifestations of vasculitis, some of which can be life-threatening, cause major organ damage,…Abstract Number: 966 • 2019 ACR/ARP Annual Meeting
Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients
Background/Purpose: Background: B-cell depletion with rituximab (RTX) is an effective treatment for ANCA-associated vasculitis (AAV) patients. Repeated RTX upon B-cell repopulation or return of ANCAs…Abstract Number: 1712 • 2019 ACR/ARP Annual Meeting
Head and Neck Involvement of IgA Vasculitis: A Case-Control Study
Background/Purpose: IgA vasculitis (IgAV) is an immune-complex mediated, small-vessel vasculitis which predominantly involves the skin on the lower extremities. Head and neck involvement is rarely…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- 35
- Next Page »